GlobalData : Despite positive efficacy data highlighted at AAN 2024, Axsome Therapeutic's ASX-07 will struggle to make significant impact in acute migraine market, says GlobalData

18 Apr, 2024 Despite positive efficacy data highlighted at AAN 2024, Axsome Therapeutic's ASX-07 will struggle to make significant impact in acute migraine market, says GlobalData
...

Related Keywords

United States ,American ,Pzifer Nurtec Rimegepant ,Philippa Salter ,Abbvie Ubrelvy ,American Academy Of Neurology ,Currax Pharmaceuticals Treximet ,American Academy ,Axsome Therapeutics ,Seniorneurology Analyst ,Currax Pharmaceuticals ,Markets ,